New FDA Policy On Diagnostics Studies “Fills A Big Gap,” CDRH Chief Says
This article was originally published in The Gray Sheet
Executive SummaryCompanies specializing in diagnostic products should pay close attention to a new, statistics-focused guidance document from FDA, device center Director Dan Schultz says
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.